Acid reflux is the backward flow of stomach contents past the lower esophageal sphincter (LES), the one-way valve at the junction of esophagus and stomach. When that reflux produces burning behind the breastbone, it is called heartburn. When reflux happens often enough or severely enough to injure the esophageal lining or cause chronic symptoms, it becomes gastroesophageal reflux disease, or GERD. The distinction matters clinically: roughly 20 percent of US adults experience weekly heartburn, but only a subset have erosive damage or complications requiring escalation beyond lifestyle change. Most people improve with three measures: smaller meals, avoiding late eating, and a trial of acid suppression.
The mechanism: why stomach acid travels the wrong way
The LES is a 3-to-4-centimeter ring of smooth muscle that maintains a resting pressure of roughly 10 to 30 mmHg, higher than the stomach's baseline pressure. Reflux happens through three distinct failures, not one.
The first is transient LES relaxation (TLESR): a sudden, prolonged drop in sphincter pressure lasting 10 to 60 seconds, not triggered by swallowing. TLESRs account for the majority of reflux episodes in healthy people and in most patients with mild GERD. The second is a mechanically weak sphincter with chronically low resting pressure, common in people with hiatal hernia, where part of the stomach slides above the diaphragm and loses the diaphragm's pinch-cock support. The third is elevated abdominal pressure overcoming a normal valve, which is why obesity, pregnancy, and tight belts worsen symptoms.
Acid is not the only offender. The refluxate contains pepsin, a proteolytic enzyme active at pH below 5, and in about 10 to 40 percent of reflux episodes the contents are weakly acidic or non-acidic, which helps explain why proton pump inhibitors (PPIs) do not eliminate all symptoms.
The esophagus has its own defenses: peristaltic clearance that sweeps refluxate back down, saliva that neutralizes residual acid, and a mucosal barrier. When clearance fails, acid contact time rises. Tissue injury begins when esophageal pH drops below 4 for more than roughly 4 to 5 percent of a 24-hour monitoring period, the conventional threshold for pathologic acid exposure on pH testing. In plain terms: it is not one splash of acid that damages tissue but the total minutes of acid contact per day.
How common it is, and the quantified burden
Heartburn is one of the most prevalent symptoms in primary care. Population surveys consistently place weekly heartburn or regurgitation at about 18 to 28 percent of US adults, with monthly symptoms in 40 percent or more. GERD prevalence has risen in parallel with obesity: body mass index above 30 roughly doubles the odds of frequent reflux symptoms compared with normal weight, and each 5-unit rise in BMI associates with a modest but measurable increase in risk.
The economic scale is large. GERD-related direct costs in the US exceed USD 9 billion annually by older estimates, and PPI prescriptions number in the tens of millions per year. Among adults with weekly symptoms, roughly 30 to 40 percent have reflux esophagitis visible on endoscopy; the remainder have non-erosive reflux disease (NERD), where symptoms occur without visible mucosal breaks.
Barrett's esophagus, the premalignant change where squamous lining is replaced by intestinal-type columnar cells, occurs in an estimated 1 to 2 percent of adults with chronic GERD symptoms and considerably less in the general population. Progression from Barrett's to esophageal adenocarcinoma is rare: annual risk is approximately 0.1 to 0.3 percent per year in unselected cohorts, which is why surveillance intervals are measured in years, not months.
A comparison: GERD presentations and what each means
| Presentation | Endoscopic finding | Typical symptom pattern | Approximate share of GERD patients | First-line approach |
|---|---|---|---|---|
| Non-erosive reflux disease | Normal mucosa | Heartburn with normal acid exposure or hypersensitive esophagus | 50-70% | Lifestyle plus on-demand or daily PPI |
| Erosive esophagitis | Visible breaks (Los Angeles grade A-D) | Heartburn, often worse after meals or lying down | 30-40% | Daily PPI for 8 weeks, then reassess |
| Reflux hypersensitivity | Normal mucosa, normal acid exposure | Symptoms with physiologic acid levels | 5-15% | Neuromodulators, pain reprocessing |
| Functional heartburn | Normal mucosa and pH study | Burning without demonstrable reflux | 5-10% | Brain-gut axis therapy |
| Barrett's esophagus | Columnar metaplasia | Often asymptomatic | 1-2% of chronic GERD | Surveillance endoscopy per interval |
The clinical lesson hidden in this table: symptoms correlate poorly with damage. A patient with severe daily heartburn may have a normal endoscopy, while a patient with Barrett's may feel nothing. That mismatch is why guidelines reserve endoscopy for alarm features rather than for symptom severity alone.
The time course: from meal to symptom to repair
| Time after eating | What happens | Clinical relevance |
|---|---|---|
| 0-15 minutes | Gastric distension triggers TLESRs; acid pocket forms at the gastroesophageal junction | The "acid pocket" floats above ingested food and is the first refluxate |
| 15-60 minutes | Reflux episodes peak; esophageal peristalsis clears most volume within 1-2 swallows | Most postprandial heartburn begins here |
| 1-3 hours | Gastric emptying continues; lying down or bending increases reflux | The reason for the "no eating 3 hours before bed" rule |
| Nighttime (sleep) | Reflux can occur without waking; saliva and swallowing stop | Nocturnal acid exposure predicts esophagitis better than daytime symptoms |
| 8 weeks of PPI therapy | Mucosal healing in most erosive esophagitis | Healing rates of 80-90% for grade A/B, lower for grade C/D |
| After PPI withdrawal | Rebound acid hypersecretion for 2-4 weeks | Abrupt cessation can cause transient symptom flare |
| Years of untreated reflux | Risk of stricture, Barrett's, rarely adenocarcinoma | Absolute cancer risk remains low (about 0.1% per year in Barrett's) |
The nighttime row deserves emphasis. Saliva flow falls by roughly 80 percent during sleep, and swallowing stops, so acid that refluxes at 2 a.m. sits in contact with the esophagus far longer than daytime reflux. This is why bedtime dosing strategy and head-of-bed elevation produce outsized effects in patients with nocturnal symptoms.
Misconceptions and non-obvious mechanisms
The most persistent misconception is that acid reflux equals too much acid. In most patients, total daily acid production is normal. The problem is location and timing. This is also why antacids give 30 to 60 minutes of relief while doing nothing for the underlying reflux episode frequency.
A second misconception concerns food triggers. Individual triggers are real but highly variable; population data do not support universal elimination of citrus, tomato, chocolate, or coffee. Systematic reviews find weak evidence for blanket dietary restriction. A better approach is a personal trigger log over 2 to 4 weeks rather than preemptive avoidance of every "acidic" food.
A third: PPIs do not work instantly. They irreversibly block the proton pump, but only pumps that are actively secreting are blocked, so maximal effect takes 3 to 5 days of daily dosing. Taking a PPI only when symptoms flare is pharmacologically the wrong pattern; it works far better taken 30 to 60 minutes before the first meal of the day.
A corrected misconception on supine positioning: elevating the head of the bed by 6 to 8 inches, using blocks or a wedge, reduces esophageal acid exposure measurably, whereas stacking pillows does not, because pillows bend the torso at the waist and can increase abdominal pressure. In plain terms: the whole bed must tilt, not just your head.
A non-obvious edge case is the "silent reflux" phenotype, laryngopharyngeal reflux (LPR), where patients present with hoarseness, throat clearing, or a globus sensation rather than heartburn. LPR is harder to diagnose, response to PPI is less predictable, and up to 50 percent of patients have minimal heartburn. Clinicians often trial twice-daily PPI for 8 to 12 weeks before concluding treatment failure.
What to actually do: concrete steps in order
Start with the measures with the best evidence-to-effort ratio, then escalate.
- Weight loss if BMI is above 25. A 10 percent body weight reduction associates with roughly 40 percent reduction in reflux symptom frequency in observational cohorts.
- Eat smaller meals, and finish eating at least 3 hours before lying down.
- Raise the head of the bed 6 to 8 inches with blocks or a wedge, not pillows.
- Trial a 2-week elimination of your own logged trigger foods, not a generic list.
- For intermittent symptoms, use an H2 blocker or antacid as needed; for frequent symptoms (2 or more days per week), discuss a daily PPI trial of 8 weeks.
- Reassess after 8 weeks rather than continuing indefinitely without review.
Red-flag symptoms that warrant prompt evaluation rather than self-treatment:
- Difficulty swallowing (dysphagia) or food sticking
- Unintentional weight loss
- Vomiting blood or black, tarry stools
- Chest pain radiating to the arm or jaw, especially with exertion (rule out cardiac cause first)
- Anemia or persistent symptoms despite 8 weeks of PPI therapy
- New symptoms after age 60
The chest pain bullet is the most important safety caveat in this entire article. Cardiac ischemia and reflux can produce identical substernal burning, and reflux is common enough that it can coexist with heart disease and mask it. Per the 2021 ACC/AHA chest pain guideline, new exertional chest discomfort should be evaluated for cardiac causes before being attributed to reflux.
Limits of the evidence and what remains uncertain
Several areas remain genuinely unsettled. Long-term PPI use is associated in observational studies with small absolute increases in fracture, kidney injury, and certain infections, but causality is disputed and confounded by indication; the absolute risk increments are typically under 1 percent per year. Patients with a clear indication, such as erosive esophagitis or Barrett's, should not stop therapy out of concern for these signals without discussion.
The role of the microbiome and of visceral hypersensitivity in NERD and functional heartburn is an active hypothesis, not established science. The relationship between reflux and sleep apnea is bidirectional and incompletely characterized. And the optimal surveillance interval for non-dysplastic Barrett's remains debated, with current practice favoring 3 to 5 years for most patients rather than annual endoscopy.
What is well established: reflux is a mechanical and clearance problem more than an acid-volume problem; symptoms and mucosal damage dissociate; nighttime reflux carries disproportionate risk; and stepwise lifestyle change followed by timed acid suppression resolves most cases. The number that best frames the whole topic is the 4 percent acid exposure threshold on pH monitoring, because it captures the core principle: it is the total minutes of contact, not the intensity of any single episode, that determines harm.